Brokerages expect Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) to announce $2.91 earnings per share for the current fiscal quarter, Zacks reports. Eight analysts have provided estimates for Jazz Pharmaceuticals’ earnings, with estimates ranging from $2.83 to $3.04. Jazz Pharmaceuticals posted earnings of $2.95 per share in the same quarter last year, which would suggest a negative year over year growth rate of 1.4%. The firm is scheduled to announce its next earnings results on Tuesday, February 26th.
According to Zacks, analysts expect that Jazz Pharmaceuticals will report full year earnings of $12.98 per share for the current year, with EPS estimates ranging from $12.89 to $13.10. For the next fiscal year, analysts anticipate that the business will post earnings of $13.82 per share, with EPS estimates ranging from $13.05 to $14.78. Zacks’ EPS averages are a mean average based on a survey of research firms that that provide coverage for Jazz Pharmaceuticals.
Jazz Pharmaceuticals (NASDAQ:JAZZ) last announced its quarterly earnings data on Tuesday, November 6th. The specialty pharmaceutical company reported $3.58 earnings per share for the quarter, topping the Zacks’ consensus estimate of $3.32 by $0.26. The business had revenue of $469.37 million for the quarter, compared to analysts’ expectations of $482.64 million. Jazz Pharmaceuticals had a net margin of 28.09% and a return on equity of 24.92%. The business’s revenue was up 14.0% compared to the same quarter last year. During the same quarter in the prior year, the company earned $3.22 earnings per share.
A number of equities research analysts have weighed in on JAZZ shares. Cowen set a $200.00 price objective on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a report on Wednesday, November 7th. Wells Fargo & Co restated a “buy” rating on shares of Jazz Pharmaceuticals in a report on Wednesday, November 7th. Royal Bank of Canada set a $184.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Piper Jaffray Companies set a $208.00 target price on shares of Jazz Pharmaceuticals and gave the stock a “buy” rating in a research note on Wednesday, November 7th. Finally, Cantor Fitzgerald reiterated a “buy” rating and issued a $201.00 target price on shares of Jazz Pharmaceuticals in a research note on Tuesday, November 6th. Six investment analysts have rated the stock with a hold rating and fourteen have given a buy rating to the stock. Jazz Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $189.76.
JAZZ traded down $2.33 during midday trading on Friday, reaching $141.17. The company’s stock had a trading volume of 975,543 shares, compared to its average volume of 729,139. The stock has a market cap of $8.66 billion, a PE ratio of 14.77, a price-to-earnings-growth ratio of 0.86 and a beta of 0.94. The company has a debt-to-equity ratio of 0.52, a quick ratio of 4.16 and a current ratio of 4.29. Jazz Pharmaceuticals has a 1 year low of $130.15 and a 1 year high of $184.00.
In related news, Director Seamus Mulligan acquired 50,000 shares of the stock in a transaction that occurred on Thursday, November 15th. The shares were bought at an average price of $144.56 per share, for a total transaction of $7,228,000.00. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CEO Bruce C. Cozadd sold 1,300 shares of the stock in a transaction that occurred on Friday, September 21st. The shares were sold at an average price of $164.36, for a total transaction of $213,668.00. Following the transaction, the chief executive officer now owns 281,215 shares in the company, valued at approximately $46,220,497.40. The disclosure for this sale can be found here. In the last quarter, insiders sold 6,600 shares of company stock worth $1,063,472. Insiders own 3.90% of the company’s stock.
A number of institutional investors have recently modified their holdings of JAZZ. BlackRock Inc. lifted its position in Jazz Pharmaceuticals by 64.0% during the second quarter. BlackRock Inc. now owns 4,372,080 shares of the specialty pharmaceutical company’s stock valued at $753,311,000 after purchasing an additional 1,706,417 shares during the period. FMR LLC lifted its position in Jazz Pharmaceuticals by 12.1% during the second quarter. FMR LLC now owns 6,634,958 shares of the specialty pharmaceutical company’s stock valued at $1,143,203,000 after purchasing an additional 715,595 shares during the period. AGF Investments Inc. bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $78,345,000. Voya Investment Management LLC bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $70,215,000. Finally, Fiera Capital Corp bought a new position in Jazz Pharmaceuticals during the second quarter valued at approximately $54,662,000. Institutional investors own 91.53% of the company’s stock.
About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.
Recommended Story: Balanced Fund
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.